Regulatory Update - GSK receives positive CHMP opinions for Tafinlar® (dabrafenib) and Tyverb® (lapatinib)
Today, GlaxoSmithKline plc (GSK) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorisation for two cancer drugs.
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Marketing | Pharmaceuticals